Abcam, ab251376, Anti-SUCLA2 antibody [EPR14924] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SUCLA2 antibody. Carrier free. Suitable for ICC/IF, WB, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR14924,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, Flow Cyt (Intra), ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab251376 is the carrier-free version of
ab202582
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SUCLA2 also known as succinate-CoA ligase (ADP-forming) subunit beta is an enzyme with a molecular mass of approximately 48 kDa. It plays an important role in the mitochondrial matrix where it participates in the citric acid cycle. The enzyme is found in various tissues with higher expression in muscle and brain tissues. SUCLA2 functions as part of the succinyl-CoA synthetase complex which catalyzes the reversible conversion of succinyl-CoA to succinate with the concurrent substrate-level phosphorylation of GDP to GTP or ADP to ATP depending on tissue type.
Biological function summary
The SUCLA2 subunit is essential for energy metabolism. It forms a component of the succinyl-CoA synthetase complex working with the alpha subunit SUCLG1. This complex supports the provision of energy by converting GDP to GTP in processes needing high energy levels critical for maintaining cellular homeostasis. Therefore it especially supports tissues with high energy demands. The action of SUCLA2 links energy production with the metabolic pathways involved in cellular respiration.
Pathways
SUCLA2 plays a critical role in the citric acid cycle also known as the Krebs cycle. Part of this cycle SUCLA2 contributes to cellular respiration and energy production. The SUCLA2 protein closely interacts with SUCLG1 to form the functional succinyl-CoA synthetase enzyme. Additionally it shows connections to the electron transport chain where the products of its catalysis are used in ATP generation. Defects in these pathways can have widespread effects on cellular energy states and mitochondrial function.
SUCLA2 mutations are linked to mitochondrial DNA depletion syndromes particularly myopathy and encephalopathy. These conditions lead to severe energy metabolism impairments due to faulty mitochondrial function. SUCLA2 has also been associated with Leigh syndrome a neurodegenerative disorder marked by compromised cellular respiration. Such disorders point towards deficient ATP synthesis highlighting the interconnected role of SUCLA2 with other mitochondrial proteins involved in cellular energy metabolism.